Cargando…
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
Clinical trials have shown that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) did not improve the survival of patients with EGFR-mutated non-small cell lung cancer (NSCLC) because of the high crossover of treatments. Realistically, the role of EGFR-TKIs in NSCLC with mutate...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5227705/ https://www.ncbi.nlm.nih.gov/pubmed/28079142 http://dx.doi.org/10.1038/srep40374 |
_version_ | 1782493857534967808 |
---|---|
author | Zhao, Dan Chen, Xuejing Qin, Na Su, Dan Zhou, Lijuan Zhang, Quan Li, Xi Zhang, Xinyong Jin, Mulan Wang, Jinghui |
author_facet | Zhao, Dan Chen, Xuejing Qin, Na Su, Dan Zhou, Lijuan Zhang, Quan Li, Xi Zhang, Xinyong Jin, Mulan Wang, Jinghui |
author_sort | Zhao, Dan |
collection | PubMed |
description | Clinical trials have shown that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) did not improve the survival of patients with EGFR-mutated non-small cell lung cancer (NSCLC) because of the high crossover of treatments. Realistically, the role of EGFR-TKIs in NSCLC with mutated EGFR is not well known. We retrospectively analysed data from patients with recurrent or metastatic NSCLC. Clinical prognostic factors were identified by Cox proportional hazards modelling. Among 503 patients, the median overall survival (OS) for all of patients was 11.7 months. Cox analysis showed that PS 0–1, recurrent disease, EGFR mutations, or EGFR-TKI treatment were associated with improved OS. In patients with EGFR-activating mutations, Cox analysis showed that patients with adenocarcinoma, recurrent disease, or EGFR-TKI treatment had significantly longer survival. Patients with EGFR-activating mutations who received EGFR-TKI therapy had a median OS of 24.3 months, which was significantly longer than those who had not received EGFR-TKI therapy (10.8 months). Patients with wild-type EGFR had a median OS of 9.7 months and Cox analysis showed that PS score and disease type were independent predictors. EGFR-TKI therapy is an independently prognostic factor for NSCLC with mutated EGFR. A more effective therapy is needed for patients with wild-type EGFR. |
format | Online Article Text |
id | pubmed-5227705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-52277052017-01-17 The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer Zhao, Dan Chen, Xuejing Qin, Na Su, Dan Zhou, Lijuan Zhang, Quan Li, Xi Zhang, Xinyong Jin, Mulan Wang, Jinghui Sci Rep Article Clinical trials have shown that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) did not improve the survival of patients with EGFR-mutated non-small cell lung cancer (NSCLC) because of the high crossover of treatments. Realistically, the role of EGFR-TKIs in NSCLC with mutated EGFR is not well known. We retrospectively analysed data from patients with recurrent or metastatic NSCLC. Clinical prognostic factors were identified by Cox proportional hazards modelling. Among 503 patients, the median overall survival (OS) for all of patients was 11.7 months. Cox analysis showed that PS 0–1, recurrent disease, EGFR mutations, or EGFR-TKI treatment were associated with improved OS. In patients with EGFR-activating mutations, Cox analysis showed that patients with adenocarcinoma, recurrent disease, or EGFR-TKI treatment had significantly longer survival. Patients with EGFR-activating mutations who received EGFR-TKI therapy had a median OS of 24.3 months, which was significantly longer than those who had not received EGFR-TKI therapy (10.8 months). Patients with wild-type EGFR had a median OS of 9.7 months and Cox analysis showed that PS score and disease type were independent predictors. EGFR-TKI therapy is an independently prognostic factor for NSCLC with mutated EGFR. A more effective therapy is needed for patients with wild-type EGFR. Nature Publishing Group 2017-01-12 /pmc/articles/PMC5227705/ /pubmed/28079142 http://dx.doi.org/10.1038/srep40374 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Zhao, Dan Chen, Xuejing Qin, Na Su, Dan Zhou, Lijuan Zhang, Quan Li, Xi Zhang, Xinyong Jin, Mulan Wang, Jinghui The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer |
title | The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer |
title_full | The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer |
title_fullStr | The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer |
title_full_unstemmed | The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer |
title_short | The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer |
title_sort | prognostic role of egfr-tkis for patients with advanced non-small cell lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5227705/ https://www.ncbi.nlm.nih.gov/pubmed/28079142 http://dx.doi.org/10.1038/srep40374 |
work_keys_str_mv | AT zhaodan theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT chenxuejing theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT qinna theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT sudan theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT zhoulijuan theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT zhangquan theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT lixi theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT zhangxinyong theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT jinmulan theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT wangjinghui theprognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT zhaodan prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT chenxuejing prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT qinna prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT sudan prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT zhoulijuan prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT zhangquan prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT lixi prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT zhangxinyong prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT jinmulan prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer AT wangjinghui prognosticroleofegfrtkisforpatientswithadvancednonsmallcelllungcancer |